{"nctId":"NCT03095521","briefTitle":"A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore Throat","startDateStruct":{"date":"2017-02-22","type":"ACTUAL"},"conditions":["Sore Throat"],"count":228,"armGroups":[{"label":"Arm A","type":"EXPERIMENTAL","interventionNames":["Drug: Angal, lozenges [menthol],"]},{"label":"Arm B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ANTI-ANGIN® FORMULA"]}],"interventions":[{"name":"Angal, lozenges [menthol],","otherNames":[]},{"name":"ANTI-ANGIN® FORMULA","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Voluntarily signed informed consent for participation in this clinical study; 18 to 45 years old inclusive, male and female;\n* Diagnosed uncomplicated acute infectious and inflammatory diseases of the pharynx, accompanied by a sore throat;\n* Onset of first symptoms of the uncomplicated acute infectious and inflammatory diseases of the pharynx (pharyngitis and/or tonsillitis) less than 48 hours prior to inclusion into the study;\n* Baseline TSS score (Tonsillopharyngitis Severity Score) ≥ 5 (total score);\n\nExclusion Criteria:\n\n* Use of analgesics within \\<12 hours prior to the study start or/and inability to cancel them during the study;\n* Use of antibiotics within \\<48 hours prior to the study start or/and inability to cancel them during the study;\n* Use of local therapy (sprays, rinses, lozenges) to pharynx within \\<12 hours before study start or/and inability to cancel them, besides study medications.\n* Use systemic or inhaled corticosteroids within ≤1 months prior to the study start and planned therapy of them during the study (besides skin means).\n* Presence of symptoms of primary bacterial pharyngitis or secondary bacterial infection (including fever over 37,5 ° C, the presence of purulent raids in the throat, severe intoxication, leukocytosis, neutrophilia, shift leukocyte left (increasing the percentage of neutrophils sticks appearance younger forms of neutrophils), increased ESR 30 mm/hr);","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Without Sore Throat According to TSS Score","description":"TSS (Tonsillopharyngitis Severity Score) is a questionnaire for evaluation of the five following symptoms severity: pharyngalgia, difficulty in swallowing, salivation, hyperemia of pharyngeal mucosa, and body temperature increase according to a 4-point scale:\n\n0 : no symptoms\n\n1. : insignificant symptom\n2. : moderate symptom\n3. : significant symptom fever\n\n0 pts : \\<37.5 °С;\n\n1. pts : 37.5 to \\<38.5 °С;\n2. pts : 38.5 to \\<39.5 °С;\n3. pts : ≥ 39.5 °С. TSS total ranges are 0-15.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.35","spread":null},{"groupId":"OG001","value":"73.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.91","spread":null},{"groupId":"OG001","value":"17.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.74","spread":null},{"groupId":"OG001","value":"8.93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"50% Reduction Tss SCORE","description":"Frequency of 50 % or more total score reduction by the TSS questionnaire completed by the Investigator relative to baseline in both Angal and ANTI-ANGIN FORMULA arms at visit 2","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.35","spread":null},{"groupId":"OG001","value":"98.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in TSS Total Score","description":"Change from baseline in TSS total score. A negative change from baseline means an improvement.TSS (Tonsillopharyngitis Severity Score) is a questionnaire for evaluation of the five following symptoms severity: pharyngalgia, difficulty in swallowing, salivation, hyperemia of pharyngeal mucosa, and body temperature increase according to a 4-point scale:\n\n0 : no symptoms\n\n1. : insignificant symptom\n2. : moderate symptom\n3. : significant symptom fever\n\n0 pts : \\<37.5 °С;\n\n1. pts : 37.5 to \\<38.5 °С;\n2. pts : 38.5 to \\<39.5 °С;\n3. pts : ≥ 39.5 °С. TSS total ranges are 0-15.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.88","spread":null},{"groupId":"OG001","value":"7.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":null},{"groupId":"OG001","value":"0.83","spread":null}]}]}]},{"type":"SECONDARY","title":"Days to Recovery, Defined by the Patient's Diary (Subjective Evaluation by the Patient)","description":"only patients for which outcomes were available were included , 111 out of 113 for Angal and 102 out of 107 for Antiangin, per protocol set","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.75","spread":"0.049"},{"groupId":"OG001","value":"3.93","spread":"0.059"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Fully Recovered up to Day 5","description":"Number of participants who fully recovered up to day 5 (the outcome of a disease according to the objective evaluation by the Investigator, the total score according to the TSS questionnaire ≤ 2)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sore Throat Intensity by 100 mm in Visual Analogue Scale Filled in by the Patient (VAS) .","description":"The VAS is a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of \"no pain at all\" and \"worst pain imaginable.\" The VAS ranges from 0 to 100. A decrease from baseline in the VAS score to reflect pain intensity indicates a decrease in pain intensity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.38","spread":"17.60"},{"groupId":"OG001","value":"66.99","spread":"18.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.35","spread":"7.96"},{"groupId":"OG001","value":"4.67","spread":"10.67"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":115},"commonTop":["dry mouth","diarrhea","cough","oropharyngeal pain","Sinus Tachicardia"]}}}